CytoDyn Inc. has successfully completed enrollment for its Phase 2 clinical study (NCT06699836) investigating leronlimab, a humanized monoclonal antibody targeting the CCR5 receptor, in combination with trifluridine and tipiracil (TAS-102) and bevacizumab for patients with CCR5-positive, microsatellite stable (MSS), relapsed/refractory metastatic colorectal cancer (mCRC). This study, named CLOVER, encompasses over 60 patients across seven clinical sites in the U.S. and aims to evaluate the efficacy of this combination therapy in a challenging patient population that has shown limited response to prior treatments.

The significance of this study lies in its potential to address a critical gap in therapeutic options for patients with mCRC, particularly those who are microsatellite stable and have progressed through multiple lines of standard therapies. Preliminary data from CytoDyn’s ongoing mCRC program have indicated promising signs of clinical and biomarker activity with leronlimab, including rapid reductions in circulating tumor DNA and modulation of immune-related markers. These findings suggest that CCR5 inhibition could enhance the anti-tumor effects of existing treatments, potentially leading to improved patient outcomes in a population with a high unmet medical need.

The completion of enrollment in the CLOVER study represents a pivotal step in advancing leronlimab’s development in oncology. As the study progresses through treatment and follow-up, the resulting data will be critical for shaping future clinical strategies and may influence the broader landscape of drug development for metastatic colorectal cancer. This research underscores the importance of exploring novel mechanisms of action, such as CCR5 modulation, in enhancing therapeutic efficacy and improving healthspan for patients facing difficult-to-treat cancers.

Source: globenewswire.com